mitoquinone and HIV-Infections

No treatment exists for mitochondrial dysfunction, a contributor to end-organ disease in human immunodeficiency virus (HIV). The mitochondrial antioxidant mitoquinone mesylate (MitoQ) attenuates mitochondrial dysfunction in preclinical mouse models of various diseases but has not been used in HIV. We used a humanized murine model of chronic HIV infection and polymerase chain reaction to show that HIV-1-infected mice treated with antiretroviral therapy and MitoQ for 90 days had higher ratios of human and murine mitochondrial to nuclear DNA in end organs compared with HIV-1-infected mice on antiretroviral therapy. We offer translational evidence of MitoQ as treatment for mitochondrial dysfunction in HIV.

Topics: Animals; Antioxidants; Disease Models, Animal; DNA, Mitochondrial; HIV Infections; Humans; Mice; Mitochondria; Organophosphorus Compounds; Ubiquinone

Topics: Animals; Disease Models, Animal; Encephalitis; HIV Infections; Mesylates; Mice; Organophosphorus Compounds; Ubiquinone